(Q53886146)

22 May 2018

title

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. (English)

1 reference

22 May 2018

0 references

0 references

0 references

5

1 reference

22 May 2018

Bo Ahrén

6

object named as

Bo Ahrén

1 reference

22 May 2018

author name string

Thomas Nyström

1

1 reference

22 May 2018

Mark K Gutniak

2

1 reference

22 May 2018

Qimin Zhang

3

1 reference

22 May 2018

Fan Zhang

4

1 reference

22 May 2018

Ake Sjöholm

7

1 reference

22 May 2018

publication date

7 September 2004

1 reference

22 May 2018

American Journal of Physiology - Endocrinology and Metabolism

published in

1 reference

22 May 2018

volume

287

1 reference

22 May 2018

page(s)

E1209-15

1 reference

22 May 2018

issue

6

1 reference

22 May 2018

Statistical methods for assessing agreement between two methods of clinical measurement

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

C-peptide increases forearm blood flow in patients with type 1 diabetes via a nitric oxide-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Drugs on the horizon for treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

GLP-1 does not acutely affect insulin sensitivity in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00237.2004

10.1152/AJPENDO.00237.2004

21 January 2018

Identifiers

DOI

1 reference

22 May 2018

PubMed ID

15353407

1 reference

22 May 2018